Prospective Multicentric Optimization and Phase I/II Study of Pretargeted Radioimmunotherapy (PRAIT) Using Anti-CEA x Anti-HSG TF2 Bispecific Antibody (bsMAb) and 177Lu-IMP-288 Peptide in Patients With CEA-expressing Small Cell Lung Carcinoma (SCLC) or CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)

Trial Profile

Prospective Multicentric Optimization and Phase I/II Study of Pretargeted Radioimmunotherapy (PRAIT) Using Anti-CEA x Anti-HSG TF2 Bispecific Antibody (bsMAb) and 177Lu-IMP-288 Peptide in Patients With CEA-expressing Small Cell Lung Carcinoma (SCLC) or CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Lutetium-177-IMP 288 (Primary) ; TF 2 (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 08 Apr 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 10 Sep 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top